Skip to main content
Log in

The Economic Impact of Parkinson’s Disease

An Estimation Based on a 3—Month Prospective Analysis

PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective:This study prospectively assesses the medical costs of Parkinson’s disease (PD).

Design:Over a period of 3 months (from July to September 1995), patients with PD documented all items of healthcare provision. These data were then used to calculate medical costs for an individual patient as well as the costs of PD. Patients and setting: We included 20 outpatients with idiopathic PD from the neurological outpatient clinic, Klinikum Grosshadern, Munich, and 20 patients from two office-based neurologists in South-West Germany.

Main results:The mean 3—month medical cost of PD in 1995 deutschmarks (DM) was 5210 ($US3390, £2240) consisting of DM1410 ($US920, £610) for care and nursing, DM1580 ($US1030, £680) for drug therapy, DM1320 ($US860, £570) for inpatient hospital care, DM40 ($US26, £17) for outpatient care and DM860 for other expenses ($US560, £370). The expenditure was related to the disease evolution. Patients complaining of one—sided symptoms [Hoehn and Yahr stage I; (HY I)] were less expensive to treat (DM1930, $US1250, £830) than patients who were severely incapacitated (HY V) [DM9740, $US6330, £4200; HY V]. After 3 to 5 years of levodopa treatment approximately 50% of patients start to experience fluctuations in motor ability and dyskinesias [Unified Parkinson’s disease rating scale, part IV (UPDRS IV)]. This onset of motor complications parallels an increase in costs. For patients who experienced motor fluctuations, annual costs were DM6550 ($US4260, £2820) compared with DM3030 ($US1960, £1300) for patients lacking this problem. Indirect non—medical costs were not calculated due to the limited number of patients. The impact of the disease on work, however, is clearly apparent from the patients’ history: 19 out of 34 patients who had already stopped working attributed this to the disease, and only 6 patients were still working at the time of the survey.

Conclusion:PD poses a major financial impact to society which is expected to increase in future years as the age distribution shifts to older age groups. On the basis of a prevalence of PD of 183 per 100 000, we calculated an annual expenditure of DM3.0 billion for the direct medical costs of PD in Germany.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984; 16: 278–82

    Article  PubMed  CAS  Google Scholar 

  2. Sutcliffe RLG, Prior R, Mawby B, et al. Parkinson’s disease in the district of the Northampton Health Authority, United Kingdom: a study of prevalence and disability. Acta Neurol Scand 1985; 72: 363–79

    Article  PubMed  CAS  Google Scholar 

  3. Mutch WJ, Dingwall—Fordyce I, Downie AW, et al. Parkinson’s disease in a Scottish city. BMJ 1986; 292: 534–6

    Article  PubMed  CAS  Google Scholar 

  4. Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, et al. Neurological disorders: course and treatment. San Diego: Academic Press, 1996: 715–72

    Google Scholar 

  5. Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 1983; 19: 253–64

    Google Scholar 

  6. Singer E. Social costs of Parkinson’s disease. J Chronic Dis 1973; 26: 243–54

    Article  PubMed  CAS  Google Scholar 

  7. Späte HF, Gemende G, Gemende I. Psychosoziale Aspekte der Langzeitbetreuung von Parkinsonkranken. Psychiatr Neurol Med Psychol (Leipz) 1988; 40: 385–94

    Google Scholar 

  8. Rinne UK. Problems associated with long—term levodopa treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1983; 95: 19–26

    Article  CAS  Google Scholar 

  9. Shindler JS, Brown R, Welburn P, et al. Measuring the quality of life of patients with Parkinson’s disease. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issuesin the 1990’s. Boston: Kluwer Academic Publishers, 1995: 289–300

    Google Scholar 

  10. Berry RA, Murphy JF. Well—being of caregivers of spouses with Parkinson’s disease. Clin Nurs Res 1995; 4: 373–86

    Article  PubMed  CAS  Google Scholar 

  11. Ziegler M, Levy E. Approche economique du cout de traitement de la maladie de parkinson. Ann Psychiatr 1990; 54: 348–53

    Google Scholar 

  12. Haycock J. Idiopathic Parkinson’s disease: the burden of illness. York: University of York, 1992

    Google Scholar 

  13. Rubenstein LM, Chrischilles EA. The impact of Parkinson’s disease on health status, health expenditures, and productivity. Pharmacoeconomics 1997; 12 (4): 486–98

    Article  PubMed  CAS  Google Scholar 

  14. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The burden of Parkinson’s disease. Mov Disord 1998; 13 (3): 406–13

    Article  PubMed  CAS  Google Scholar 

  15. Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population—based studies. Epilepsy Res 1994; 18: 249–60

    Article  PubMed  CAS  Google Scholar 

  16. Gessner U, Sagmeister M, Horisberger B. The cost of epilepsy in Switzerland. Int J Health Sci 1993; 4: 121–8

    Google Scholar 

  17. Swingler RJ, Davidson DL, Roberts RC, et al. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994; 3: 115–20

    Article  PubMed  CAS  Google Scholar 

  18. Davidson DLW, Swingler RJ, Moulding F. The cost of epilepsy in patients attending an out—patient clinic. Seizure 1992; Suppl. A: P12–3

    Google Scholar 

  19. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230–43

    Article  PubMed  CAS  Google Scholar 

  20. Reinharz D, Kennedy W, Contandriopoulos AP, et al. The economic effects of introducing Vigabatrin, a new antiepileptic medication. Pharmacoeconomics 1995; 8 (5): 400–9

    Article  PubMed  CAS  Google Scholar 

  21. Stewart WF, Lipton RB. The economic and social impact of migraine. Eur Neurol 1994; 34 Suppl. 2: 12–7

    Article  Google Scholar 

  22. de Lissovoy G, Lazarus SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: S56–62

    Google Scholar 

  23. Osterhaus JT, Gutterman DG, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2 (1): 67–76

    Article  PubMed  CAS  Google Scholar 

  24. Cull RE, Wells NEJ. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15

    Google Scholar 

  25. Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994; 84: 1261–4

    Article  PubMed  CAS  Google Scholar 

  26. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer’s disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221–4

    PubMed  CAS  Google Scholar 

  27. Weinberger M, Gold DT, Divine GW, et al. Expenditures incaring for patients with dementia who live at home. Am J Public Health 1993; 83: 338–41

    Article  PubMed  CAS  Google Scholar 

  28. Huang L, Cartwright WS, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988; 103: 3–7

    PubMed  CAS  Google Scholar 

  29. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42

    Article  PubMed  CAS  Google Scholar 

  30. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52

    Article  PubMed  CAS  Google Scholar 

  31. Gershanik OS. Drug—induced movement disorders. Curr Opin Neurol Neurosurg 1993; 6: 369–76

    PubMed  CAS  Google Scholar 

  32. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease II. New York: Macmillan, 1987: 153–63

    Google Scholar 

  33. Gerstenbrand F, Poewe WH. The classification of Parkinson’s disease. In: Stern M, editor. Parkinson‘s disease. London: 1986: 315–31

    Google Scholar 

  34. Marsden CD, Parkes JD, Quinn NP. Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 96–122

    Google Scholar 

  35. Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034–8

    Article  PubMed  CAS  Google Scholar 

  36. Rosser R. A health index and output measure. In: Walker SR, Rosser RM, editors. Quality of life: assessment and application. Lancaster: MTP Press Ltd., 1988: 133–60

    Google Scholar 

  37. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1–30

    Article  PubMed  CAS  Google Scholar 

  38. Rosser R, Kind P, Williams A. Valuation of quality of life: some psychometric evidence. In: Jones-Lee M. The value of life and society. Amsterdam: Elsevier—North Holland, 1982

    Google Scholar 

  39. Drummond MF, Soddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1986

  40. International Medical Publications (IMP) Kommunikation. Gelbe liste pharmaindex. München: IMP, 1995

    Google Scholar 

  41. Bundesverband der pharmazeutischen industrie. Rote Liste 1995. Frankfurt: Cantor—Verlag, 1995

    Google Scholar 

  42. Statistisches Bundesamt. Statistisches Jahrbuch. Wiesbaden: Metzler—Poeschel—Verlag, 1995

    Google Scholar 

  43. Mundenbruch R. Gebührenordnung für Ärzte, GOÄ, BGGOÄ. Dachau: Zauner Druck und Verlags GmbH, 1994

    Google Scholar 

  44. Mundenbruch R. BMÄ, E-GO, EBM. Dachau: Zauner Druck und Verlags GmbH, 1995

  45. Robinson R. What does it mean? BMJ 1993; 307: 670–3

    Article  PubMed  CAS  Google Scholar 

  46. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13 (1): 1–7

    Article  PubMed  CAS  Google Scholar 

  47. Hill AB, Hill ID. Principles of medical statistics. London: Edward Arnold, 1991

    Google Scholar 

  48. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–71

    Article  PubMed  Google Scholar 

  49. Ransmayer G, Kuenig G, Neubauer M, et al. Effect of age and disease duration on parkinsonian motor scores under levodopatherapy. J Neural Transm Park Dis Dement Sect 1995; 9: 177–88

    Article  Google Scholar 

  50. Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson’s disease. Mov Disord 1998; 13: 249–54

    Article  PubMed  CAS  Google Scholar 

  51. Glasziou PP, Bromwich S, Simes RJ. Quality of life six monthsafter myocardial infarction treated with thrombolytic therapy. Med J Aust 1994; 161: 532–6

    PubMed  CAS  Google Scholar 

  52. Magee TR, Scott DJ, Dunkley A, et al. Quality of life following surgery for abdominal aortic aneurysm. Br J Surg 1992; 79: 1014–1019

    Article  PubMed  CAS  Google Scholar 

  53. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844–9

    PubMed  CAS  Google Scholar 

  54. Burstall ML. Copayments for medicines: how much should patients pay? Pharmacoeconomics 1994; 6 (3): 187–92

    Article  PubMed  CAS  Google Scholar 

  55. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 96–101

    Article  PubMed  CAS  Google Scholar 

  56. Dodel RC, Pepperl S, Koehne-Volland R, et al. Kosten neurologischer Erkrankungen: M. Parkinson, Epilepsie, Dystonien. Med Klin 1996; 91: 479–85

    CAS  Google Scholar 

  57. Hardie R. Levodopa—related motor fluctuations. In: Stern GM, editor. Parkinson’s disease. London: Chapman and Hall Medical, 1986: 559–96

    Google Scholar 

  58. Dodel RC, Eggert K, Oertel WH. Costs of Parkinson’s disease: a preliminary study. In: Stern MB, editor. Beyond the decade of the brain. Kent: Wells Medical, 1994: 59–73

    Google Scholar 

  59. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11 Suppl. 1: 200–5

    Google Scholar 

  60. Factor SA, Weiner SJ. Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 1993; 8: 257–62

    Article  PubMed  CAS  Google Scholar 

  61. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson’s disease. Can J Neurol Sci 1992; 19: 108–12

    PubMed  CAS  Google Scholar 

  62. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson’s disease. Neurology 1994; 44 Suppl. 10: S9–51

    Google Scholar 

  63. Mauskopf J, Schulman K, Bell L, et al. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. Pharmacoeconomics 1996; 9 (3): 264–77

    Article  PubMed  CAS  Google Scholar 

  64. Kleinhenz J, Vieregge P, Fassl H, et al. Prävalenz des Morbus Parkinson in der Bundesrepublik Deutschland. Offentl Gesundheitswes 1990; 52: 181–90

    PubMed  CAS  Google Scholar 

  65. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35: 841–5

    Article  PubMed  CAS  Google Scholar 

  66. Mayeux R, Denaro J, Hermenegildo N, et al. Population—based investigation of Parkinson’s disease with and without dementia. Arch Neurol 1992; 49: 492–7

    Article  PubMed  CAS  Google Scholar 

  67. Organization for Economic Cooperation and Development (OECD). Health data file. Washington, DC: OECD, 1996

    Google Scholar 

  68. Schwabe U. Parkinsonmittel. In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport’ 95. Stuttgart: G. Fischer-Verlag, 1995: 357–9

    Google Scholar 

  69. Marsden CD. Parkinson’s disease. Lancet 1990; 335: 948–52

    Article  PubMed  CAS  Google Scholar 

  70. West R. Parkinson’s disease. London: Office of Health Economics, 1991

    Google Scholar 

  71. Rosati G, Granieri E, Pinna L, et al. The risk of Parkinson disease in mediterranean people. Neurology 1980; 30: 250–5

    Article  PubMed  CAS  Google Scholar 

  72. Granieri E, Carreras M, Casetta M, et al. Parkinson’s disease in Ferrara, Italy, 1967-1987. Arch Neurol 1991; 48: 854–7

    Article  PubMed  CAS  Google Scholar 

  73. Tandberg E, Larsen JP, Nessler EG, et al. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord 1995; 10: 541–9

    Article  PubMed  CAS  Google Scholar 

  74. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer’s disease care. Health Aff 1993; 12: 164–76

    Article  CAS  Google Scholar 

  75. Hu T, Huang L, Cartwright W. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158–63

    Article  PubMed  CAS  Google Scholar 

  76. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. Cincinnati: H. Whitney Books, 1996

    Google Scholar 

  77. Singer E. The effect of treatment with levodopa on Parkinson patients’ social functioning and outlook on life. J Chronic Dis 1974; 27: 581–94

    Article  PubMed  CAS  Google Scholar 

  78. Meenan RF, Yelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: a patient orientated study of chronic disease costs. Arthritis Rheum 1978; 21: 827–33

    Article  PubMed  CAS  Google Scholar 

  79. Jönsson B, Rehnberg C, Borgquist L, et al. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand 1994; 63: 207–12

    Google Scholar 

  80. Stone CE. The lifetime costs of rheumatoid arthritis. J Rheumatol 1984; 11: 819–27

    PubMed  CAS  Google Scholar 

  81. Maier-Hoehn MM. The natural history of Parkinson’s disease in the pre—levodopa and post—levodopa eras. Neurol Clin 1992; 30: 331–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodel, R.C., Singer, M., Köhne-Volland, R. et al. The Economic Impact of Parkinson’s Disease. Pharmacoeconomics 14, 299–312 (1998). https://doi.org/10.2165/00019053-199814030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814030-00006

Keywords

Navigation